Improved PFS and OS With Ixazomib Plus Lenalidomide-Dexamethasone (IRd) vs Placebo-Rd in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM): Final Data From the Phase 3 China Continuation of TOURMALINE-MM1

被引：0
|
作者：
Hou, Jian [1 ]
Jin, Jie [2 ]
Xu, Yan [3 ]
Wu, Depei [4 ]
Ke, Xiaoyan [5 ]
Daobin, Zhou [6 ]
Lu, Jin [7 ]
Du, Xin [8 ]
Chen, Xiequn [9 ]
Li, Junmin [10 ]
Liu, Jing [11 ]
Gupta, Neeraj [12 ]
Hanley, Michael [12 ]
Li, Hongmei [12 ]
Hua, Zhaowei [12 ]
Wang, Bingxia [12 ]
Zhang, Xiaoquan [12 ]
Wang, Hui [12 ]
van de Velde, Helgi [12 ]
Richardson, Paul [13 ]
Moreau, Philippe [14 ]
机构：
[1] Second Mil Med Univ, ChangZheng Hosp, Shanghai, Peoples R China
[2] Zhe Jiang Med Univ, Hosp Affiliated 1, Hangzhou, Zhejiang, Peoples R China
[3] Chinese Acad Med Sci, Inst Hematol & Blood Dis, Tianjin, Peoples R China
[4] Soochow Univ, Affiliated Hosp 1, Suzhou, Peoples R China
[5] Beijing Med Univ, Affiliated Hosp 3, Beijing, Peoples R China
[6] Peking Univ, Med Coll Hosp, Beijing, Peoples R China
[7] Peking Univ, Peoples Hosp, Beijing, Peoples R China
[8] Guangdong Prov Peoples Hosp, Guangzhou, Guangdong, Peoples R China
[9] Fourth Mil Med Univ, Xijing Hosp, Xian, Peoples R China
[10] Shanghai Jiao Tong Univ, Ruijin Hosp, Shanghai, Peoples R China
[11] Hosp Xiang Ya Med Univ, Hosp 3, Changsha, Hunan, Peoples R China
[12] Millennium Pharmaceut Inc, Cambridge, MA USA
[13] Dana Farber Canc Inst, Boston, MA 02115 USA
[14] CHU Nantes, Univ Hosp Hotel Dieu HME, Nantes, France
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2017年 / 17卷 / 01期
关键词：
D O I：
10.1016/j.clml.2017.03.121
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PS-119
引用
收藏
页码：E67 / E67
页数：1
相关论文
共 50 条
  • [41] Progression-Free Survival (PFS) According to the Presence of Adverse Cytogenetic Abnormalities in Patients (pts) with Multiple Myeloma (MM) Receiving Ixazomib (ixa)-Based vs Placebo (pbo)-Based Therapy: A Pooled Analysis of the TOURMALINE-MM1, MM2, MM3, and MM4 Phase 3 Studies
    Chng, Wee-Joo
    Lonial, Sagar
    Morgan, Gareth J.
    Iida, Shinsuke
    Moreau, Philippe
    Kumar, Shaji
    Twumasi-Ankrah, Philip
    Kumar, Arun
    Dash, Ajeeta B.
    Vorog, Alexander
    Zhang, Xiaoquan
    Suryanarayan, Kaveri
    Labotka, Richard
    Dimopoulos, Meletios A.
    Rajkumar, S. Vincent
    [J]. BLOOD, 2021, 138
  • [42] Longer Time to Best Response and Depth of Response Are Associated with Improved Duration of Best Achieved Response and Progression-Free Survival (PFS): Post-Hoc Analysis of Phase 3 Tourmaline-MM1 Trial in Relapsed/Refractory Multiple Myeloma (RRMM)
    Garderet, Laurent
    Laubach, Jacob P.
    Stoppa, Anne-Marie
    Hari, Parameswaran
    Cavo, Michele
    Ludwig, Heinz
    Mateos, Maria-Victoria
    Luptakova, Katarina
    Lin, Jianchang
    van de Velde, Helgi
    Berg, Deborah
    Moreau, Philippe
    Richardson, Paul G.
    [J]. BLOOD, 2016, 128 (22)
  • [43] Impact of Elotuzumab Plus Pomalidomide/Dexamethasone on Health-Related Quality of Life for Patients with Relapsed/Refractory Multiple Myeloma ( RRMM): Final Data from the Phase 2 ELOQUENT-3 Trial
    Weisel, Katja
    Dimopoulos, Meletios A.
    San-Miguel, Jesus
    Paner, Agne
    Engelhardt, Monika
    Taylor, Fiona
    Lord-Bessen, Jennifer
    Yao, David
    Yip, Christine
    Greenwood, Mike
    Tang, Jackson
    Cavo, Michele
    [J]. BLOOD, 2021, 138
  • [44] Updates from ICARIA-MM, a Phase 3 Study of Isatuximab (Isa) Plus Pomalidomide and Low-Dose Dexamethasone (Pd) vs Pd in Relapsed and Refractory Multiple Myeloma (RRMM)
    Richardson, Paul G.
    Perrot, Aurore
    San-Miguel, Jesus
    Beksac, Meral
    Spicka, Ivan
    Leleu, Xavier
    Schjesvold, Fredrik
    Moreau, Philippe
    Dimopoulos, Meletios A.
    Huang, Jeffrey Shang-Yi
    Minarik, Jiri
    Cavo, Michele
    Prince, H. Miles
    Zheng, Cheng
    Dubin, Franck
    van de Velde, Helgi
    Anderson, Kenneth C.
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S423 - S424
  • [45] Daratumumab (DARA) in combination with bortezomib plus dexamethasone (D-Vd) or lenalidomide plus dexamethasone (D-Rd) in relapsed or refractory multiple myeloma (RRMM): Subgroup analysis of the phase 3 CASTOR and POLLUX studies in patients (pts) with early or late relapse after initial therapy.
    Spencer, Andrew
    Moreau, Philippe
    Mateos, Maria-Victoria
    Goldschmidt, Hartmut
    Suzuki, Kenshi
    Levin, Mark-David
    Sonneveld, Pieter
    Yoon, Sung-Soo
    Usmani, Saad Zafar
    Weisel, Katja
    Reece, Donna Ellen
    Ahmadi, Tahamtan
    Pei, Huiling
    Mayo, Wendy Garvin
    Gai, Xue
    Carey, Jodi
    Carson, Robin L.
    Dimopoulos, Meletios A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [46] Oral ixazomib (Ixa), IV daratumumab (Dara), and dexamethasone (dex; IDd) in relapsed/refractory multiple myeloma (RRMM) patients (pts) with 1-3 prior therapies: phase 2 study interim analysis (IA)
    Orlowski, Robert
    Delimpasi, Sosana
    Straub, Jan
    Symeonidis, Argiris
    Pour, Ludek
    Hajek, Roman
    Touzeau, Cyrille
    Bhanderi, Viralkumar
    Pavlicek, Petr
    Robak, Pawel
    Berdeja, Jesus G.
    Matous, Jeffrey V.
    Karlin, Lionel
    Zweegman, Sonja
    Grosicki, Sebastian
    Pluta, Andrzej
    Kambhampati, Suman
    Suryanarayan, Kaveri
    Twumasi-Ankrah, Philip
    Dash, Ajeeta
    Labotka, Richard
    Dimopoulos, Meletios-Athanasios
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S154 - S155
  • [47] Pomalidomide (POM), bortezomib, and low-dose dexamethasone (PVd) vs bortezomib and low-dose dexamethasone (Vd) in lenalidomide (LEN)-exposed patients (pts) with relapsed or refractory multiple myeloma (RRMM): Phase 3 OPTIMISMM trial.
    Richardson, Paul G.
    Rocafiguera, Albert Oriol
    Beksac, Meral
    Liberati, Anna Marina
    Galli, Monica
    Schjesvold, Fredrik
    Lindsay, Jindriska
    Weisel, Katja
    White, Darell
    Facon, Thierry
    San-Miguel, Jesus
    Sunami, Kazutaka
    O'Gorman, Peter
    Sonneveld, Pieter
    Yu, Xin
    Doerr, Thomas
    Bensmaine, Amine
    Zaki, Mohamed H.
    Anderson, Kenneth Carl
    Dimopoulos, Meletios A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [48] ELOQUENT-2 Update: A Phase 3, Randomized, Open-Label Study of Elotuzumab in Combination with Lenalidomide/Dexamethasone (ELd) vs Lenalidomide/Dexamethasone (Ld) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)-3-Year Safety and Efficacy Follow-up
    Dimopoulos, M.
    Lonial, S.
    White, D.
    Moreau, P.
    Palumbo, A.
    San Miguel, J.
    Shpilberg, O.
    Anderson, K.
    Grosicki, S.
    Spicka, I.
    Walter-Croneck, A.
    Magen-Nativ, H.
    Mateos, M. -V
    Belch, A.
    Reece, D.
    Beksac, M.
    Bleickardt, E.
    Poulart, V.
    Katz, J.
    Singhal, A. K.
    Richardson, P.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 122 - 123
  • [49] Updated Progression-Free Survival (PFS) and Overall Survival (OS) with Melflufen and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 2 Study O-12-M1
    Bringhen, Sara
    Voorhees, Peter M.
    Plesner, Torben
    Mellqvist, Ulf-Henrik
    Reeves, Brandi
    Sonneveld, Pieter
    Byrne, Catriona
    Nordstrom, Eva
    Harmenberg, Johan
    Obermueller, Jakob
    Richardson, Paul G.
    [J]. BLOOD, 2019, 134
  • [50] Efficacy and Safety of Oral Ixazomib (Ixa), Intravenous (IV) Daratumumab (Dara), and IV/Oral Dexamethasone (Dex; IDd) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) and 1-3 Prior Therapies: Results of the Final Analysis of a Phase 2 Study
    Delimpasi, Sosana
    Dimopoulos, Meletios A.
    Straub, Jan
    Symeonidis, Argiris
    Hajek, Roman
    Touzeau, Cyrille
    Bhanderi, Viralkumar K.
    Berdeja, Jesus
    Pavlicek, Petr
    Matous, Jeffrey, V
    Robak, Pawel J.
    Suryanarayan, Kaveri
    Villareal, Miguel
    Cherepanov, Dasha
    Srimani, Jaydeep K.
    Yao, Huilan
    Labotka, Richard
    Orlowski, Robert Z.
    [J]. BLOOD, 2022, 140 : 9995 - 9997
12345